At Bayer, we are relentlessly searching for ways to help improve people’s lives, including those suffering from functional gastrointestinal disorders (FGIDs). We know patients with FGIDs can suffer multiple symptoms with varying onset, severity and duration and may prefer a simple and clinically proven herbal treatment option.

Iberogast® is our herbal over the counter (OTC) medicine, which consists of a unique combination of 9 herbal extracts. It is indicated for the relief of gastrointestinal symptoms including those of functional dyspepsia (FD) and irritable bowel syndrome (IBS). Iberogast is one of the most studied herbal OTC medicines, supported by the highest level of evidence.

This October in Barcelona we will hold the first ever international symposium at UEG Week on FGIDs and Iberogast®.

Leading international gastroenterologists will deliver cutting edge discussions on the latest research in the field of FGIDs, as well as provide an overview of the robust scientific and clinical data available on Iberogast.

Three local gastroenterologists will also be participating in the symposium and will share their learnings following the event via video and a symposium summary. We plan to make these available in the healthcare professional section on www.iberogast.com.au.

If you are attending UEG Week 2017, we welcome your attendance at the Iberogast symposium. It will give you an opportunity to ask questions to renowned international experts or trigger discussions that reflect your most burning practise issues.

The symposium will be held at 6pm on 29 October 2017 in Room E1, Fira de Barcelona, Gran Via North Access, Barcelona, Spain.

Please see agenda and international contributors overleaf.

Iberogast contains *Iberis amara*, *Angelica archangelica*, *Matricaria chamomilla* and *Carum carvi*. For full active ingredients, see the label.
SPEAKERS

Prof. Fermín Mearin, Barcelona, Spain
Introduction: Functional dyspepsia (FD) and irritable bowel syndrome (IBS): Complex disorders with complex treatments

Prof. Vincenzo Stanghellini, Bologna, Italy
FD and IBS pathophysiology: Beyond ROME IV

Prof. Hans-Dieter Allescher, Garmisch-Partenkirchen, Germany
STW-5 mechanisms of action in FD and IBS: The origin of multi-target

Prof. Peter Malfertheiner, Magdeburg, Germany
Clinical evidence of the efficacy of STW-5 in FD and IBS

Ass. Prof. Tatyana Lapina, Moscow, Russia
STW-5: Clinical experience in everyday practice

IF YOU ARE ATTENDING UEG WEEK, PLEASE COME ALONG ON 29 OCTOBER 2017 AT 6PM TO ROOM E1, FIRA DE BARCELONA, GRAN VIA NORTH ACCESS, BARCELONA, SPAIN

This meeting is arranged and sponsored by Bayer Consumer Health Division L.AU.MKTG.10.2017.01304